The Zhitong Finance App learned that on September 18, the NMPA official website showed that Lilly Pharmaceuticals (LLY.US)'s new Class 5.1 drug “ceptinib tablets” was approved for marketing in China. According to public information, this is the first time that a ceptinib tablet dosage form has been approved in China. Selpercatinib (Selpercatinib) is a first-of-its-kind small molecule RET inhibitor with high selectivity and inhibitory activity. It has central nervous system (CNS) activity and can inhibit various RET variants. This drug is the world's first approved highly selective RET inhibitor, which works by inhibiting the activity of abnormal RET kinase.

Screenshot source: NMPA official website

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.